Endothelin-converting enzyme inhibitors: Their application in cardiovascular diseases;Inibidores da enzima de conversão da endotelina e sua aplicação na patologia cardiovascular

Revista Portuguesa de Cardiologia

Volumn 27, Issue 3, 2008, Pages 385-408

  Cerdeira, Ana Sofia ^a   Brás Silva, Carmen ^a   Leite Moreira, Adelino F ^a  

^a University of Porto   (Portugal)

Author keywords

Cardiovascular diseases; Endothelin; Endothelin converting enzyme; Endothelin converting enzyme inhibitors; Heart; Therapeutics

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; 5,6,8,13 TETRAHYDRO 1,6,9,14 TETRAHYDROXY 3 (2 HYDROXYPROPYL) 7 METHOXY 8,13 DIOXOBENZO[A]NAPHTHACENE 2 CARBOXYLIC ACID; AMBRISENTAN; BENAZEPRIL; BOSENTAN; DAGLUTRIL; DARUSENTAN; ENDOTHELIN CONVERTING ENZYME INHIBITOR; PHOSPHORAMIDON; SITAXSENTAN;

CARDIOVASCULAR DISEASE; CHAGAS DISEASE; DRUG EFFICACY; DRUG HALF LIFE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; NONHUMAN; PULMONARY HYPERTENSION; RESTENOSIS; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MICE; RATS;

EID: 43049105055     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T, 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415.
2. Brunner F, Bras-Silva C, Cerdeira AS, Leite-Moreira AF, 2006. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 111, 508-531.
3. Tanowitz HB, Huang H, Jelicks LA, Chandra M, Loredo ML, Weiss LM, Factor SM, Shtutin V, Mukherjee S, Kitsis RN, Christ GJ, Wittner M, Shirani J, Kisanuki YY, Yanagisawa M, 2005. Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease. Infect Immun 73, 2496-2503.
4. Luscher TF, Barton M, 2000. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102, 2434-2440.
5. Attina T, Camidge R, Newby DE, Webb DJ, 2005. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 91, 825-831.
6. Masaki T, Vane JR, Vanhoutte PM, 1994. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev 46, 137-142.
7. Leite-Moreira AF, Bras-Silva C, 2004. Inotropic effects of ETB receptor stimulation and their modulation by endocardial endothelium, NO, and prostaglandins. Am J Physiol Heart Circ Physiol 287, H1194-1199.
8. Masaki T, Ninomiya H, Sakamoto A, Okamoto Y, 1999. Structural basis of the function of endothelin receptor. Mol Cell Biochem 190, 153-156.
9. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T, 1989. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 86, 2863-2867.
10. Saida K, Mitsui Y, Ishida N, 1989. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity. J Biol Chem 264, 14613-14616.
11. McMahon EG, Palomo MA, Moore WM, McDonald JF, Stern MK, 1991. Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci U S A 88, 703-707.
12. Okada K, Miyazaki Y, Takada J, Matsuyama K, Yamaki T, Yano M, 1990. Conversion of big endothelin-1 by membrane-bound metalloendopeptidase in cultured bovine endothelial cells. Biochem Biophys Res Commun 171, 1192-1198.
13. D'Orleans-Juste P, Plante M, Honore JC, Carrier E, Labonte J, 2003. Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol 81, 503-510.
14. Turner AJ, Isaac RE, Coates D, 2001. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23, 261-269.
15. Ikeda K, Emoto N, Raharjo SB, Nurhantari Y, Saiki K, Yokoyama M, Matsuo M, 1999. Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides. J Biol Chem 274, 32469-32477.
16. Valdenaire O, Richards JG, Faull RL, Schweizer A, 1999. XCE, a new member of the endothelin-converting enzyme and neutral endopeptidase family, is preferentially expressed in the CNS. Brain Res Mol Brain Res 64, 211-221.
17. Valdenaire O, Rohrbacher E, Langeveld A, Schweizer A, Meijers C, 2000. Organization and chromosomal localization of the human ECEL1 (XCE) gene encoding a zinc metallopeptidase involved in the nervous control of respiration. Biochem J 346 Pt 3, 611-616.
18. Benoit A, Vargas MA, Desgroseillers L, Boileau G, 2004. Endothelin-converting enzyme-like 1 (ECEL1) is present both in the plasma membrane and in the endoplasmic reticulum. Biochem J 380, 881-888.
19. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M, 1994. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78, 473-485.
20. Emoto N, Yanagisawa M, 1995. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 270, 15262-15268.
21. Hasegawa H, Hiki K, Sawamura T, Aoyama T, Okamoto Y, Miwa S, Shimohama S, Kimura J, Masaki T, 1998. Purification of a novel endothelin-converting enzyme specific for big endothelin-3. FEBS Lett 428, 304-308.
22. Schweizer A, Valdenaire O, Nelbock P, Deuschle U, Dumas Milne Edwards JB, Stumpf JG, Loffler BM, 1997. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem J 328 ( Pt 3), 871-877.
23. Brown CD, Barnes K, Turner AJ, 2000. Functional significance of the isoforms of endothelin-converting enzyme-1. J Cardiovasc Pharmacol 36, S26-27.
24. Valdenaire O, Lepailleur-Enouf D, Egidy G, Thouard A, Barret A, Vranckx R, Tougard C, Michel JB, 1999. A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter: molecular cloning and characterization. Eur J Biochem 264, 341-349.
25. Valdenaire O, Rohrbacher E, Mattei MG, 1995. Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J Biol Chem 270, 29794-29798.
26. Ikeda S, Emoto N, Alimsardjono H, Yokoyama M, Matsuo M, 2002. Molecular isolation and characterization of novel four subisoforms of ECE-2. Biochem Biophys Res Commun 293, 421-426.
27. Lorenzo MN, Khan RY, Wang Y, Tai SC, Chan GC, Cheung AH, Marsden PA, 2001. Human endothelin converting enzyme-2 (ECE2): characterization of mRNA species and chromosomal localization. Biochim Biophys Acta 1522, 46-52.
28. Yanagisawa H, Yanagisawa M, Kapur RP, Richardson JA, Williams SC, Clouthier DE, de Wit D, Emoto N, Hammer RE, 1998. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 125, 825-836.
29. Schmidt M, Kroger B, Jacob E, Seulberger H, Subkowski T, Otter R, Meyer T, Schmalzing G, Hillen H, 1994. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett 356, 238-243.
30. Sonnenberg JL, Sakane Y, Jeng AY, Koehn JA, Ansell JA, Wennogle LP, Ghai RD, 1988. Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides 9, 173-180.
31. Dumoulin MJ, Adam A, Blais C, Jr., Lamontagne D, 1998. Metabolism of bradykinin by the rat coronary vascular bed. Cardiovasc Res 38, 229-236.
32. Trapani AJ, Beil ME, Bruseo CW, Savage P, Firooznia F, Jeng AY, 2004. CGS 35601 and its Orally Active Prodrug CGS 37808 as Triple Inhibitors of Endothelin-converting Enzyme-1, Neutral Endopeptidase 24.11, and Angiotensin-Converting Enzyme. J Cardiovasc Pharmacol 44 Suppl 1, S211-215.
33. Tsurumi Y, Ohhata N, Iwamoto T, Shigematsu N, Sakamoto K, Nishikawa M, Kiyoto S, Okuhara M, 1994. WS79089A, B and C, new endothelin converting enzyme inhibitors isolated from Streptosporangium roseum. No. 79089. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) 47, 619-630.
34. Tsurumi Y, Ueda H, Hayashi K, Takase S, Nishikawa M, Kiyoto S, Okuhara M, 1995. WS75624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. No. 75624. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) 48, 1066-1072.
35. Takaishi S, Tuchiya N, Sato A, Negishi T, Takamatsu Y, Matsushita Y, Watanabe T, Iijima Y, Haruyama H, Kinoshita T, Tanaka M, Kodama K, 1998. B-90063, a novel endothelin converting enzyme inhibitor isolated from a new marine bacterium, Blastobacter sp. SANK 71894. J Antibiot (Tokyo) 51, 805-815.
36. Muller DN, Mullally A, Dechend R, Park JK, Fiebeler A, Pilz B, Loffler BM, Blum-Kaelin D, Masur S, Dehmlow H, Aebi JD, Haller H, Luft FC, 2002. Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension 40, 840-846.
37. Jeng AY, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Trapani AJ, 2000. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066. J Cardiovasc Pharmacol 36, S36-39.
38. Ahn K, Sisneros AM, Herman SB, Pan SM, Hupe D, Lee C, Nikam S, Cheng XM, Doherty AM, Schroeder RL, Haleen SJ, Kaw S, Emoto N, Yanagisawa M, 1998. Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem Biophys Res Commun 243, 184-190.
39. Umekawa K, Hasegawa H, Tsutsumi Y, Sato K, Matsumura Y, Ohashi N, 2000. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme. Jpn J Pharmacol 84, 7-15.
40. Kukkola PJ, Savage P, Sakane Y, Berry JC, Bilci NA, Ghai RD, Jeng AY, 1995. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 26 Suppl 3, S65-68.
41. De Lombaert S, Ghai RD, Jeng AY, Trapani AJ, Webb RL, 1994. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem Biophys Res Commun 204, 407-412.
42. Trapani AJ, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Jeng AY, 2000. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11. Life Sci 67, 1025-1033.
43. Jeng AY, Savage P, Beil ME, Bruseo CW, Hoyer D, Fink CA, Trapani AJ, 2002. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11. Clin Sci (Lond) 103 Suppl 48, 98S-101S.
44. Tabrizchi R, 2003. SLV-306. Solvay. Curr Opin Investig Drugs 4, 329-332.
45. De Lombaert S, Blanchard L, Berry C, Ghai RD, Trapani AJ, 1995. Non-peptidic inhibitors of neutral endopeptidase 24.11 - 2. Design and pharmacology of orally active phosphonate prodrugs. Bioorganic and Medicinal Chemistry Letters 5, 151-154(154).
46. Trapani AJ, Beil ME, Bruseo CW, Fink CA, Hoyer D, Savage P, Jeng AY, 2002. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats. Clin Sci (Lond) 103 Suppl 48, 102S-106S.
47. Meil J, Wurl M, Thormählen D, Rose H. Pharmacology of the active metabolite of SLV 306: A mixed inhibitor of NEP and ECE. Nau Schi Arch Pharmacol. 1998;358(Suppl 1):R513.
48. Meil J, Rupp H, Thormählen D, Rose H. In-vivo results with SLV 306, an orally active inhibitor of NEP and ECE. Naunyn-Schmied Arch Pharmacol 1998, 358(1, Suppl. 2): R 514
49. Seed A, Kuc RE, Davenport A, Ashby M, Hiller C, De Voogd H, Essers H, McMurray J, 2003. First demonstration in humans of systemic neutral endopeptidase and endothelin converting enzyme inhibition using a new, orally active dual metalloprotease inhibitor SLV 306. Journal of the American College of Cardiology 265A
50. Vemulapalli S, Chintala M, Stamford A, Watkins R, Chiu P, Sybertz E, Fawzi A, 1997. Renal effects of SCH 54470: a triple inhibitor of ECE, ACE, and NEP. Cardiovascular Drug Reviews 15, 260-272.
51. Jeng AY, Mulder P, Kwan AL, Battistini B, 2002. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Can J Physiol Pharmacol 80, 440-449.
52. Ksander GM, Savage P, Trapani AJ, Balwierczak JL, Jeng AY, 1998. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 31 Suppl 1, S71-73.
53. Alberola Aguilar AM, Revert F, Moya A, Beltran J, Garcia J, San Martin E, Sancho S, Such L, 2000. Intravenous BQ-123 and phosphoramidon reduce ventricular ectopic beats and myocardial infarct size in dogs submitted to coronary occlusion and reperfusion. Gen Pharmacol 35, 143-147.
54. Martin P, Tzanidis A, Stein-Oakley A, Krum H, 2000. Effect of a highly selective endothelin-converting enzyme inhibitor on cardiac remodeling in rats after myocardial infarction. J Cardiovasc Pharmacol 36, S367-370.
55. Pham D, Jeng AY, Plante S, Escher E, Battistini B, 2002. Inhibition of endothelin-converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery. Can J Physiol Pharmacol 80, 450-457.
56. Minamino T, Kurihara H, Takahashi M, Shimada K, Maemura K, Oda H, Ishikawa T, Uchiyama T, Tanzawa K, Yazaki Y, 1997. Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation 95, 221-230.
57. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., Jacobs AK, Kern MJ, King SB, 3rd, Morrison DA, O'Neil WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, 2006. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113, e166-286.
58. Takahashi T, Kanda T, Inoue M, Sumino H, Kobayashi I, Iwamoto A, Nagai R, 1998. Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Life Sci 63, PL137-143.
59. Kirshbom PM, Tsui SS, DiBernardo LR, Meliones JN, Schwinn DA, Ungerleider RM, Gaynor JW, 1995. Blockade of endothelin-converting enzyme reduces pulmonary hypertension after cardiopulmonary bypass and circulatory arrest. Surgery 118, 440-444; discussion 444-445.
60. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ, 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328, 1732-1739.
61. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K, 1993. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 73, 887-897.
62. Yorikane R, Miyauchi T, Sakai S, Sakurai T, Yamaguchi I, Sugishita Y, Goto K, 1993. Altered expression of ETB-receptor mRNA in the lung of rats with pulmonary hypertension. J Cardiovasc Pharmacol 22 Suppl 8, S336-338.
63. Kirshbom PM, Page SO, Jacobs MT, Tsui SS, Bello E, Ungerleider RM, Schwinn DA, Gaynor JW, 1997. Cardiopulmonary bypass and circulatory arrest increase endothelin-1 production and receptor expression in the lung. J Thorac Cardiovasc Surg 113, 777-783.
64. Galie N, Manes A, Branzi A, 2004. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61, 227-237.
65. Okada M, Yamashita C, Okada M, Okada K, 1995. Role of endothelin-1 in beagles with dehydromonocrotaline-induced pulmonary hypertension. Circulation 92, 114-119.
66. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, Wharton J, 2002. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 165, 398-405.
67. MacLean MR, McCulloch KM, Baird M, 1995. Effects of pulmonary hypertension on vasoconstrictor responses to endothelin-1 and sarafotoxin S6C and on inherent tone in rat pulmonary arteries. J Cardiovasc Pharmacol 26, 822-830.
68. McCulloch KM, Docherty CC, Morecroft I, MacLean MR, 1996. EndothelinB receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol 119, 1125-1130.
69. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G, 2002. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346, 896-903.
70. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, van Giersbergen PL, 2003. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 73, 372-382.
71. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G, 2004. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24, 353-359.
72. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF, Simonneau G, 2004. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170, 1212-1217.
73. Hoeper MM, Kramm T, Wilkens H, Schulze C, Schafers HJ, Welte T, Mayer E, 2005. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128, 2363-2367.
74. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M, 2006. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114, 48-54.
75. Langleben D, Brock T, Dixon R, Barst R, 2004. STRIDE 1: Effects of the Selective ETA Receptor Antagonist, Sitaxsentan Sodium, in a Patient Population with Pulmonary Arterial Hypertension that Meets Traditional Inclusion Criteria of Previous Pulmonary Arterial Hypertension Trials. J Cardiovasc Pharmacol 44, S80-S84.
76. Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ, 2004. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothehn-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 126, 1377-1381.
77. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N, 2006. Treatment of pulmonary arterial hypertension with the selective endothehn-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47, 2049-2056.
78. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ, 2005. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46, 529-535.
79. Jasmin JF, Lucas M, Cernacek P, Dupuis J, 2001. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 103, 314-318.
80. Vemulapalli S, Watkins RW, Brown A, Cook J, Bernardino V, Chiu PJ, 1993. Disparate effects of phosphoramidon on blood pressure in SHR and DOCA-salt hypertensive rats. Life Sci 53, 783-793.
81. McMahon EG, Palomo MA, Brown MA, Bertenshaw SR, Carter JS, 1993. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats. Am J Hypertens 6, 667-673.
82. Battistini B, Ayach B, Molez S, Blouin A, Jeng AY, 2002. Effects of benazepril, an angiotensin-converting enzyme inhibitor, combined with CGS 35066, a selective endothelin-converting enzyme inhibitor, on arterial blood pressure in normotensive and spontaneously hypertensive rats. Clin Sci (Lond) 103 Suppl 48, 363S-366S.
83. Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, Beaudoin M, Belleville K, Sirois P, Nantel F, Jeng AY, Battistini B, 2005. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens 18, 1606-1613.
84. Daull P, Blouin A, Belleville K, Beaudoin M, Arsenault D, Leonard H, Sirois P, Nantel F, Jeng AY, Battistini B, 2006. Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats. Exp Biol Med (Maywood) 231, 830-833.
85. Solvay's novel therapeutic agent SLV306 shows its early promise for the treatment of hypertension and congestive heart failure. Solvay Pharmaceuticals Inc. Press release, September 14 2001.
86. Wada A, Tsutamoto T, Ohnishi M, Sawaki M, Fukai D, Maeda Y, Kinoshita M, 1999. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Circulation 99, 570-577.
87. Wang X, Ohnishi M, Wada A, Tsutamoto T, Sawaki M, Fujii M, Matsumoto T, Yamamoto T, Kurokawa K, Yamada H, Kinoshita M, 2001. Endothelin-1 promotes vascular structural remodeling during the progression of heart failure: prevention of vascular remodeling using a specific endothelin-converting enzyme inhibitor. Life Sci 69, 2477-2488.
88. Wada A, Ohnishi M, Tsutamoto T, Fujii M, Matsumoto T, Yamamoto T, Wang X, Kinoshita M, 2002. Chronic effects of an endothelin-converting enzyme inhibitor on cardiorenal and hormonal function in heart failure. Clin Sci (Lond) 103 Suppl 48, 254S-257S.
89. Mulder P, Barbier S, Monteil C, Jeng AY, Henry JP, Renet S, Thuillez C, 2004. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure. J Cardiovasc Pharmacol 43, 489-494.
90. Fontaine ER, Viau S, Jasmin G, Dumont L, 1998. Effects of phosphoramidon, BQ 788, and BQ 123 on coronary and cardiac dysfunctions of the fading hamster heart. J Cardiovasc Pharmacol 32, 12-20.
91. Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M, 2005. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 45, 1145-1152.
92. Mellin V, Jeng AY, Monteil C, Renet S, Henry JP, Thuillez C, Mulder P, 2005. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition. J Cardiovasc Pharmacol 46, 390-397.
93. Mylona P, Cleland JG, 1999. Update of REACH-1 and MERIT-HF chnical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1, 197-200.
94. Kalra PR, Moon JC, Coats AJ, 2002. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85, 195-197.
95. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, Demets DL, 2005. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11, 12-20.
96. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJ, 1996. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 94, 2131-2137.
97. Bayes M, Rabasseda X, Prous JR, 2003. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 25, 831-855.
98. Dickstein K, De Voogd HJ, Miric MP, Willenbrock R, Mitrovic V, Pacher R, Koopman PA, 2004. Effect of single doses of SLV306, an Inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 94, 237-239.
99. Jelicks LA, Chandra M, Shtutin V, Petkova SB, Tang B, Christ GJ, Factor SM, Wittner M, Huang H, Douglas SA, Weiss LM, Orleans-Juste PD, Shirani J, Tanowitz HB, 2002. Phosphoramidon treatment improves the consequences of chagasic heart disease in mice. Clin Sci (Lond) 103 Suppl 48, 267S-271S.
100. Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, Clouthier DE, Yanagisawa M, 2000. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 105, 1373-1382.
101. Fernandez-Patron C, Radomski MW, Davidge ST, 1999. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85, 906-911.
102. Hoang MV, Turner AJ, 1997. Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem J 327 ( Pt 1), 23-26.
103. Johnson GD, Stevenson T, Ahn K, 1999. Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. J Biol Chem 274, 4053-4058.
104. Barker S, Khan NQ, Wood EG, Corder R, 2001. Effect of an antisense oligodeoxynucleotide to endothelin-converting enzyme-1c (ECE-1c) on ECE-1c mRNA, ECE-1 protein and endothelin-1 synthesis in bovine pulmonary artery smooth muscle cells. Mol Pharmacol 59, 163-169.